Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01812759 · ClinicalTrials.gov registry record · Phase 4
Fentanyl for Breakthrough Pain in the Emergency Department
A Phase 4 study, sponsored by M.D. Anderson Cancer Center.
- Terminated
- Registry status
- Phase 4
- Development phase
- 3
- Enrollment target
NCT01812759: Clinical Trial Phase 4 study, sponsored by M.D. Anderson Cancer Center.
NCT01812759 is a Phase 4 study that was terminated before completion, run by M.D. Anderson Cancer Center. The registered enrollment target is 3 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01812759, a Phase 4 study, was terminated before completion, sponsored by M.D. Anderson Cancer Center.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 3 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to learn if fentanyl nasal spray can help decrease pain related to cancer when used with other drugs for pain. Researchers also want to know if this drug can help decrease the length of your stay in the Emergency Department. In this study, fentanyl nasal spray will be compared to a placebo nasal spray. A placebo is not a drug. It looks like the study drug but it is not designed to treat any disease or illness. It is designed in this study to be compared with the study spray to learn if the study spray has any real effect. You will also be given intravenous (IV) pain drugs. You will be given these drugs even if you decide not to take part in this study.
Interventions
- OTHER Placebo Nasal Spray
- DRUG Hydromorphone PCA
- DRUG Fentanyl Nasal Spray
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2014-01-10 |
| Est. Completion | 2014-10-22 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01812759
The ClinicalTrials.gov registry entry for NCT01812759 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo Nasal Spray is the first listed.
NCT01812759 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01812759 about?
NCT01812759 is a clinical study titled "Fentanyl for Breakthrough Pain in the Emergency Department". The goal of this clinical research study is to learn if fentanyl nasal spray can help decrease pain related to cancer when used with other drugs for pain. Researchers also want to know if this drug can help decrease the length of your stay in the Emergency Department. In this study, fentanyl nasal ...
What is the current status of trial NCT01812759?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 3 participants. The study started on 2014-01-10. Estimated completion is 2014-10-22.
What interventions are being tested in trial NCT01812759?
The interventions under investigation include: Placebo Nasal Spray (OTHER), Hydromorphone PCA (DRUG), Fentanyl Nasal Spray (DRUG).
Who is sponsoring clinical trial NCT01812759?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.